EDUCATE! 📣EMPOWER!📣 Prof FMiller shares adaptive measures against predicted impacts of #climate change on rheumatic diseases. 📍We all have a role to play in this. @RheumNow #ACR21 #MedTwitter #RheumTwitter https://t.co/asJcnm104k

An important slide showing how UV radiation affects #Immunity 🔅suppress APCs 🔅promotes #cytokine production 🔅inhibits cytotoxic & memory T cells 🔅⬆ monocyte recruitment 👉⬆ IFN 🔸⬆UV exposure, ⬆ risk of dev't/flares of #lupus, DM @RheumNow #ACR21 #climatechange https://t.co/e9glxfy6wR

Interim analysis of AURORA 2 Extension study: 🦋Voclosporin maintained meaningful reductions in UPCR and eGFR remained stable until month 30. 🦋No unexpected new AEs Promising results! @RheumNow #ACR21 #ACRBest abs1425 https://t.co/hBB6k0bDYb

Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS) Dr. Sheila Reyes, ( @RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21. https://t.co/Q50kEr5WEU https://t.co/5DScK5krtw

• https://bit.ly/3BW0op9

CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY

• Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes …

AxSpA: Geographic Prevalence Association with HLA-B27: Dr. Rachel Tate ( @uptoTate ) Dr. Rachel Tate discusses abstract #0368 presented at the #ACR21 annual meeting. https://t.co/CnIjlWuKjZ https://t.co/vytIdK9CCo

• https://bit.ly/3H4HSP9

#ACR21 #Abstr1457 Nine more well-phenotyped patients with VEXAS were presented. New info: 💠Peritubular capillaritis & cryo vasculitis 💠Most cs- & bDMARDs had limited efficacy 💠Potential therapy with plasma cell blockade & stem cell transplant @RheumNow https://t.co/iDwJAdbf4M https://t.co/X4ENz4M91u

• Clinical Heterogeneity of the VEXAS Syndrome: A Case Series - ACR Meeting Abstr…

This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24. Reassuring data. @RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx

Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC ) #ACR21 https://t.co/0zskkywWu1 https://t.co/n3qs19rQNG

• https://bit.ly/3wt5M1V

Interesting results where cannabidiol NEG results in RCT in hand OA and PsA. ? Throw out the ‘pot’with the dish water? Did it stimulate appetites? Was pain the same but interference less? Abst#1456 #ACR21 @RheumNow https://t.co/rnz82Paxkr

• Richard Conway on Twitter: "Dr Vela presents DB RCT on cannabidiol in hand…

Interesting question came up: why would you change a RA patient from JAKi to JAKi? The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way). That would clearly favour to better survival #ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit

• Richard Conway on Twitter: "JAK-pot registry-based study. Following JAKi f…

#ACR21 #Abstr1484 Hands down one of the most impressive results and trial design. RHAPSODY: Rilonacept led to ⬇️risk of pericarditis recurrence vs PBO (7% vs 74%; HR 0.04). Median time to resolution of pain and CRP were 5 & 7 Days. FDA approved @RheumNow https://t.co/Zty2WnkJEQ https://t.co/xGqt9Lwvjj

• RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes a…